ECTE Pengajuan SEC - Echo Therapeutics Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1031927

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Echo Therapeutics Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

April 21, 2017	8-K	Other Events SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2017 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (Co
April 6, 2017	SC 13D	ECTE / Echo Therapeutics, Inc. / Schoenbart Alan Wayne - PRIMARY DOCUMENT Activist Investment SC 13D 1 ecte13dmar212017.htm PRIMARY DOCUMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ECHO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) K
March 31, 2017	NT 10-K	Echo Therapeutics PRIMARY DOCUMENT SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35218 CUSIP Number: 27876L107 (Check One:) (X) Form 10-K ( ) Form 20-F ( ) Form 11-K ( ) Form 10-Q ( ) Form 10-D ( ) Form N-SAR ( ) Form N-CSR For Period Ended: December 31, 2016 ( ) Transition Report on Form 10-K ( ) Transition Report on Form 10-Q ( ) Tr
March 21, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2017 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (Co
February 2, 2017	8-K	Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 28, 2017 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (
December 27, 2016	EX-99.1	ECHO THERAPEUTICS ANNOUNCES DISMISSAL OF FEDERAL COURT ACTION SEC Connect Exhibit 99.1 ECHO THERAPEUTICS ANNOUNCES DISMISSAL OF FEDERAL COURT ACTION Iselin, NJ-December 21, 2016/PRN Newswire/Echo Therapeutics, Inc. (OTCQB:ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM), today announced that on Monday, December 19, 2016, in response to the Company’s notice filed in Court seeking the dismissal of the action captioned
December 27, 2016	8-K	Financial Statements and Exhibits, Other Events SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation)
December 14, 2016	8-K	Financial Statements and Exhibits, Other Events SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation)
December 14, 2016	EX-99.1	ECHO THERAPEUTICS ANNOUNCES FEDERAL COURT’S DENIAL OF PRELIMINARY INJUNCTION AND LIFTING OF TEMPORARY RESTRAINING ORDER SEC Connect Exhibit 99.1 ECHO THERAPEUTICS ANNOUNCES FEDERAL COURT?S DENIAL OF PRELIMINARY INJUNCTION AND LIFTING OF TEMPORARY RESTRAINING ORDER Iselin, NJ ? December 12, 2016/PRN Newswire/Echo Therapeutics, Inc. (OTCQB:ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM), today announced that on Friday, December 9, 2016, the U.S. District Court for the South
December 2, 2016	8-K	Other Events SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 193 4 Date of report (Date of earliest event reported): November 30, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation)
December 1, 2016	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 28, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation)
December 1, 2016	EX-16.1	Tel: 732-750-0900 EX-16.1 2 ex16-1.htm LETTER ON CHANGE IN CERTIFYING ACCOUNTANT Exhibit 16.1 Tel: 732-750-0900 90 Woodbridge Center Dr., 4th Floor Fax: 732-750-1222 Woodbridge, NJ 07095 www.bdo.com December 1, 2016 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on November 28, 2016,
November 23, 2016	EX-10.2	PROMISSORY NOTE (Bridge Note) 10.2 Exhibit 10.2 PROMISSORY NOTE (Bridge Note) $875,000 Iselin, NJ November 18, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the “Borrower”), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of NETWORK VICTORY LIMITED (together with any successors or
November 23, 2016	EX-10.1	Amendment # 2 to the License, Development and Commercialization Agreement Echo Therapeutics, Inc. Medical Technologies Innovations, Asia, Ltd. 10.1 Exhibit 10.1 Amendment # 2 to the License, Development and Commercialization Agreement Between Echo Therapeutics, Inc. And Medical Technologies Innovations, Asia, Ltd. 1 EXECUTIVE SUMMARY 1.1 Scope. This amendment covers the activities necessary to support the Chinese commercialization of the ?Core 2+ and ?Generation 3? versions of the Echo CGM system, as defined below. This Amendment # 2 wil
November 23, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ECTE 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 18, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (Com
November 16, 2016	10-Q	Echo Therapeutics FORM 10-Q (Quarterly Report) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-35218 ECHO THERAPEUTICS, INC.
November 14, 2016	NT 10-Q	Echo Therapeutics 0-Q Echo Therapeutics, Inc. - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 00023017 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form
October 19, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ecte8koct192016 SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 19, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) Blueprint Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $125,000 Iselin, NJ October 19, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the “Borrower”), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of NETWORK VICTORY LIMITED ( together with any successo
September 27, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (
September 23, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 ecte8ksep232016.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdi
September 23, 2016	EX-10.2	SEPARATION AGREEMENT ex10-2.htm Exhibit 10.2 SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (the “Agreement”) is made and entered into as of September 22, 2016 (the “Effective Date”) by and between ECHO THERAPEUTICS, INC., a Delaware corporation with its principal office located at 99 Wood Avenue South, Iselin, NJ 08830 (together with its subsidiaries, affiliates, successors and assigns) (referred to as the “Company”)
September 23, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $250,000 Iselin, NJ September 23, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of NETWORK VICTORY LIMITED ( together with any succe
August 12, 2016	10-Q	Echo Therapeutics FORM 10-Q (Quarterly Report) ecte10qjune302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-35218 E
July 8, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ecte8kjuly82016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporatio
June 23, 2016	CORRESP	Echo Therapeutics ESP echocorrespjune232016.htm ECHO THERAPEUTICS, INC. 99 Wood Avenue South, Suite 302 Iselin, New Jersey 08830 June 23, 2016 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Mail Stop 3030 Attn: Amanda Ravitz, Assistant Director Re: Echo Therapeutics, Inc. Registration Statement on Form S-3 Filed June 10, 2016 File No. 333-211975 Request for Acceleration of Effect
June 10, 2016	S-3	Echo Therapeutics FORM S-3 echos3june102016.htm As filed with the Securities and Exchange Commission on June 10, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Echo Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1649949 (State or other jurisdiction of (I.R.S. Employer in
June 3, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ecte8kjun012016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporatio
June 3, 2016	EX-3.2	AMENDED AND RESTATED BY-LAWS ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through June 1, 2016 TABLE OF CONTENTS ex3-2.htm Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through June 1, 2016 TABLE OF CONTENTS Article 1 Stockholders 1.1 Place of Meetings 1.2 Annual Meeting 1.3 Special Meetings 1.4 Notice of Meetings 1.5 List of Stockholders 1.6 Quorum 1.7 Adjournments 1.8 Voting and Proxies 1.9 Action at Meeting Article 2 Directors 2.1 Genera
May 26, 2016	8-K	Submission of Matters to a Vote of Security Holders ecte8kmay262016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporatio
May 20, 2016	10-Q	Echo Therapeutics FORM 10-Q (Quarterly Report) ecte10qmar312016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016. or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-3521
May 16, 2016	NT 10-Q	Echo Therapeutics 0-Q NT 10-Q 1 form12b25-05162016050501.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 00023017 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N-S
May 13, 2016	S-8	Echo Therapeutics ectes8may2016.htm As filed with the Securities and Exchange Commission on May 13, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Echo Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1649949 (State or other jurisdiction of incorporation or organi
May 6, 2016	424B3	ECHO THERAPEUTICS, INC. 2,655,613 Shares of Common Stock ecte424b3may2016.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-210738 PROSPECTUS ECHO THERAPEUTICS, INC. 2,655,613 Shares of Common Stock This prospectus relates solely to the resale by the selling stockholders named in this prospectus (the ?Selling Stockholders?) of up to an aggregate of 2,655,613 shares of our common stock issuable (i) upon conversion of 10% senior secured convertibl
May 4, 2016	EX-10.5	PROMISSORY NOTE ex10-5.htm Exhibit 10.5 PROMISSORY NOTE $770,000 May 2, 2016 FOR VALUE RECEIVED, BEIJING YI TANG BIO SCIENCE & TECHNOLOGY, LTD., (together with its successors and assigns, the “Borrower”), with its principal place of business at ROOM 1107, No.1 Building, No29 Nanmofang Road, Chaoyang District, Beijing 100022 P.R. China promises to pay to the order of ECHO THERAPEUTICS, INC. (together with any succ
May 4, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ecte8kapr292016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
May 4, 2016	EX-10.2	SECURED CONVERTIBLE NOTE DUE _________, 2017 ex10-2.htm Exhibit 10-2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFE
May 4, 2016	EX-10.3	CLASS B COMMON STOCK PURCHASE WARRANT ECHO THERAPEUTICS, INC. ex10-3.htm Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC
May 4, 2016	EX-3.1	Certificate of Amendment Certificate of Designation, Preferences and Rights of Series F Convertible Preferred Stock Echo Therapeutics, Inc. ex3-1.htm Exhibit 3.1 Certificate of Amendment to Certificate of Designation, Preferences and Rights of Series F Convertible Preferred Stock of Echo Therapeutics, Inc. Echo Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”), DOES HEREBY CERTIFY AS FOLLOWS: FIRST: The Certificate of Designation, Preferences and Rights
May 4, 2016	EX-10.4	PROMISSORY NOTE (Bridge Note) ex10-4.htm Exhibit 10.4 PROMISSORY NOTE (Bridge Note) $50,000 Iselin, NJ April 29, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of BEIJING YI TANG BIO SCIENCE & TECHNOLOGY, LTD. togethe
April 26, 2016	CORRESP	Echo Therapeutics ESP ECHO THERAPEUTICS, INC. 99 Wood Avenue South, Suite 302 Iselin, New Jersey 08830 April 26, 2016 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Amanda Ravitz, Assistant Director Re: Echo Therapeutics, Inc. Registration Statement on Form S-3 Filed April 14, 2016 File No. 333-210738 Request for Acceleration of Effectiveness Dear Ms. Ravitz: Pursuant to Ru
April 19, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant echo8kapr182016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
April 19, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $450,000 Iselin, NJ April 18, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of PLATINUM PARTNERS VALUE ARBITRAGE FUND, L.P., togethe
April 14, 2016	8-K	Submission of Matters to a Vote of Security Holders ecte8kapr142016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
April 14, 2016	S-3	Echo Therapeutics FORM S3 ectes3apr132016.htm As filed with the Securities and Exchange Commission on April 14, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Echo Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1649949 (State or other jurisdiction of (I.R.S. Employer in
April 13, 2016	DEFA14A	Echo Therapeutics DEFA 14A echodefa14amay2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru
April 13, 2016	DEF 14A	Echo Therapeutics DEFINITIVE SCHEDULE 14A DEF 14A 1 echodef14amay2016.htm DEFINITIVE SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Co
April 6, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant echo8kapr042016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporati
April 6, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $350,000 Iselin, NJ April 4, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of PLATINUM PARTNERS VALUE ARBITRAGE FUND, L.P., together
March 30, 2016	10-K	Echo Therapeutics FORM 10-K (Annual Report) ecte10kdec312015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-35218 ECHO THERAPEUTICS, INC. (Exact n
March 30, 2016	EX-21.1	SUBSIDIARIES OF THE REGISTRANT EX-21.1 2 ex21-1.htm SUBSIDIARIES OF THE COMPANY. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Sontra Medical, Inc. Delaware
March 22, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events ecte8kmar212016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
March 22, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm PROMISSORY NOTE (Bridge Note) $150,000 Iselin, NJ March 21, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the “Borrower”), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of PLATINUM PARTNERS VALUE ARBITRAGE FUND, L.P., together with any su
March 14, 2016	DEFA14A	Echo Therapeutics DEFA 14A DEFA14A 1 echodefamar2016.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as
March 10, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ecte8kmar92016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporatio
March 4, 2016	DEFA14A	Echo Therapeutics 14A DEFA14A 1 echodefafeb2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitte
March 4, 2016	DEF 14A	Echo Therapeutics DEF 14A echodeffeb2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 1
February 22, 2016	PRE 14A	Echo Therapeutics Form PRE 14A PRE 14A 1 echoprefeb2016.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p
February 12, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $100,000 Iselin, NJ February 11, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of PLATINUM PARTNERS VALUE ARBITRAGE FUND, L.P., toge
February 12, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant echo8kfeb112016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorpo
February 10, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm PROMISSORY NOTE (Bridge Note) $300,000 Iselin, NJ February 4, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of BEIJING YI TANG BIO SCIENCE & TECHNOLOGY, LTD. together with any
February 10, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ecte8kfeb2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
February 3, 2016	EX-10.2	SECURED CONVERTIBLE NOTE DUE JANUARY 28, 2017 ex10-2.htm Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFE
February 3, 2016	EX-10.1	SECURITIES PURCHASE AGREEMENT ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January 29, 2016, between Echo Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to
February 3, 2016	EX-10.4	REGISTRATION RIGHTS AGREEMENT ex10-4.htm Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of January 29, 2016, by and among Echo Therapeutics, Inc., a Delaware corporation, with headquarters located at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830 (the "Company"), and the investors listed on the Schedule of Purchasers attached hereto (each, a "Purchaser" and coll
February 3, 2016	EX-10.3	CLASS A COMMON STOCK PURCHASE WARRANT ECHO THERAPEUTICS, INC. ex10-3.htm Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC
February 3, 2016	EX-10.5	SECURITY AGREEMENT ex10-5.htm Exhibit 10.5 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 29, 2016 (this ?Agreement?), is among Echo Therapeutics, Inc., a Delaware corporation (the ?Company?), each Subsidiary of the Company which shall become a party to this Agreement by execution and delivery of the form annexed hereto as Annex A and the Subsidiary Guaranty annexed thereto (each such Subsidiary, a
February 3, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant echo8kfeb2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
February 1, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $200,000 Iselin, NJ January 26, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of BEIJING YI TANG BIO SCIENCE & TECHNOLOGY, LTD. toge
February 1, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant echo8kfeb2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
January 12, 2016	8-K	Echo Therapeutics FORM 8-K (Current Report/Significant Event) ecte8kjan62016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
January 12, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $X,000 City, state January XX, 2016 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the “Borrower”), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of _together with any successors or assigns, the “Lende
January 8, 2016	8-K	Echo Therapeutics FORM 8-K (Current Report/Significant Event) ecte8kjan62016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2016 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
January 6, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 echo8k12312015.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdict
January 6, 2016	EX-10.1	PROMISSORY NOTE (Bridge Note) ex10-1.htm Exhibit 10.1 PROMISSORY NOTE (Bridge Note) $X,000 City, state December XX, 2015 FOR VALUE RECEIVED, ECHO THERAPEUTICS INC., a Delaware corporation (together with its successors and assigns, the ?Borrower?), with its principal place of business at 99 Wood Avenue South, Suite 302, Iselin, New Jersey 08830, promises to pay to the order of together with any successors or assigns, the ?Lende
December 28, 2015	EX-99.1	Echo Therapeutics Appoints Elazer Edelman, M.D., Ph.D., to Board of Directors. ex99-1.htm Exhibit 99.1 Echo Therapeutics Appoints Elazer Edelman, M.D., Ph.D., to Board of Directors. ISELIN, N.J., Dec. 28, 2015 /PRNewswire/ - Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced the appointment of Elazer Edelman, M.D., Ph.D. to its Board of Directors. Currently
December 28, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (Commission
November 16, 2015	10-Q	UNITED STATES 10-Q 1 ecte10qsep302015.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015. or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission
October 29, 2015	8-K	Echo Therapeutics FORM 8-K (Current Report/Significant Event) echo8koct262015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorpor
September 30, 2015	8-K	Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities ecte8ksept242015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incor
September 30, 2015	EX-10.1	W I T N E S S E T H: ex10-1.htm Exhibit 10.1 SUBSCRIPTION AGREEMENT (this ?Agreement?) made as of the 24th day of September 2015 between ECHO THERAPEUTICS, INC., a Delaware corporation with a principal place of business at 99 Wood Avenue South, Iselin, New Jersey 08830 (the ?Company?), and with a principal place of business at (the ?Subscriber?). W I T N E S S E T H: WHEREAS, the Company desires to sell and the Subscr
September 9, 2015	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K 1 ecte8ksep32015.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdict
September 9, 2015	EX-3.1	CERTIFICATE OF INCREASE SHARES DESIGNATED SERIES F CONVERTIBLE PREFERRED STOCK ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) * * * * * ex3-1.htm Exhibit 3.1 CERTIFICATE OF INCREASE OF SHARES DESIGNATED AS SERIES F CONVERTIBLE PREFERRED STOCK OF ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) * * * * * Echo Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify: FIRST: That the Certificate
September 2, 2015	EX-10.1	W I T N E S S E T H: ex10-1.htm Exhibit 10.1 SUBSCRIPTION AGREEMENT (this ?Agreement?) made as of the day of 2015 between Echo Therapeutics, Inc., a Delaware corporation with a principal place of business at 99 Wood Avenue South, Iselin, New Jersey 08830 (the ?Company?), and [] with a principal place of business at [] (the ?Subscriber?). W I T N E S S E T H: WHEREAS, the Company desires to sell and the Subscriber desi
September 2, 2015	8-K	Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fi
August 21, 2015	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ecte8kaug202015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorpora
August 21, 2015	EX-99.1	By Electronic Delivery to: [email protected] 805 King Farm Blvd. Rockville, MD 20850 / USA Nasdaq.com ex99-1.htm Exhibit 99.1 By Electronic Delivery to: [email protected] 805 King Farm Blvd. Rockville, MD 20850 / USA Nasdaq.com August 20, 2015 Mr. Alan W. Schoenbart Chief Financial Officer Echo Therapeutics, Inc. 99 Wood Avenue South, Suite 302 Iselin, NJ 08830 Re: Echo Therapeutics, Inc. (the ?Company?) Nasdaq Symbol: ECTE Dear Mr. Schoenbart: I am following up on our recent telephone conver
August 14, 2015	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015.
July 20, 2015	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits ecte8kjuly172015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
July 20, 2015	EX-10.1	LEASE TERMINATION AGREEMENT ex10-1.htm Exhibit 10.1 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (“Agreement”) is made this 17th day of July, 2015, by and between EXETER 10 FORGE, LLC, a Delaware limited liability company (“Landlord”), and ECHO THERAPEUTICS, INC., a Delaware corporation (“Tenant”). BACKGROUND A. Landlord (as successor in interest to Forge Park Investors LLC and CRP-2 Forge, LLC) and Tenant (a
July 7, 2015	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 4, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporation) (Commission File
May 15, 2015	EX-10.1	METRO CORPORATE CAMPUS I 99 WOOD AVENUE SOUTH ISELIN, NEW JERSEY 08837 STANDARD OFFICE LEASE Exhibit 10.1 METRO CORPORATE CAMPUS I 99 WOOD AVENUE SOUTH ISELIN, NEW JERSEY 08837 STANDARD OFFICE LEASE 1. Basic Lease Provisions. 1.1. Parties: This Lease (this “Lease” or the “Lease”), dated for reference purposes only January 20, 2015, is made by and between THE REALTY ASSOCIATES FUND X, L.P., a Delaware limited partnership ("Landlord") and ECHO THERAPEUTICS, INC., a Delaware corporation ("Te
May 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015.
May 15, 2015	EX-10.3	OFFICE LEASE AGREEMENT FERRIS DEVELOPMENT 352 TURNPIKE RD, LLC, a Massachusetts limited liability company doing business as 295 Foster Street ("LANDLORD") ECHO THERAPEUTICS, INC., a Delaware corporation ('TENANT") For Premises Located at 295 Foster S Exhibit 10.3 OFFICE LEASE AGREEMENT BETWEEN FERRIS DEVELOPMENT 352 TURNPIKE RD, LLC, a Massachusetts limited liability company doing business as 295 Foster Street ("LANDLORD") AND ECHO THERAPEUTICS, INC., a Delaware corporation ('TENANT") For Premises Located at 295 Foster Street, Littleton, Massachusetts TABLE OF CONTENTS 1. Basic Lease Information 2. Lease Grant. 3. Possession 4. Rent. 5. Compli
April 20, 2015	10-Q/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No.
April 16, 2015	8-K	Echo Therapeutics FORM 8-K (Current Report/Significant Event) ecte8kapr152015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 001-35218 41-1649949 (State or other jurisdiction of Incorporat
April 16, 2015	EX-99.1	Echo Therapeutics, Inc. Announces 2014 Financial Results ex99-1.htm Exhibit 99.1 Echo Therapeutics, Inc. Announces 2014 Financial Results Iselin, NJ – April 15, 2015 – Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced financial results for the year ended December 31, 2014. Echo’s Annual Report on Form 10-K, as filed with the SEC, will be ava
April 15, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) R ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2014 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-35218 ECHO THERAPEUTICS, INC.
April 15, 2015	EX-10.43	Amendment to License, Development and Commercialization Agreement Exhibit 10.43 Amendment to License, Development and Commercialization Agreement This Amendment to License, Development and Commercialization Agreement (this “Amendment”) is entered into as of the 29 day of December, 2014 (the “Amendment Date”) by and between Echo Therapeutics, Inc., having offices at 8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 USA (“Echo”), and Medical Tec
April 15, 2015	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Sontra Medical, Inc. Delaware
April 15, 2015	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fil
April 15, 2015	EX-10.40	SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTORS LISTED ON THE SIGNATURE PAGES HERETO ECHO THERAPEUTICS, INC. DECEMBER 18, 2014 TABLE OF CONTENTS Exhibit 10.40 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTORS LISTED ON THE SIGNATURE PAGES HERETO AND ECHO THERAPEUTICS, INC. DECEMBER 18, 2014 TABLE OF CONTENTS Page SECTION 1. INTERPRETATION OF THIS AGREEMENT 1 1.1 Defined Terms 1 SECTION 2. AUTHORIZATION OF SHARES; PURCHASE AND SALE OF SHARES 4 2.1 Authorization of Securities 2.2 Issuance of Securities 4 2.3 Closing and Closing Date
April 15, 2015	EX-10.39	Platinum Partners Value Arbitrage Fund L.P. c/o Platinum Partners 250 West 55th Street, 14th Floor New York, NY 10019 Exhibit 10.39 Platinum Partners Value Arbitrage Fund L.P. c/o Platinum Partners 250 West 55th Street, 14th Floor New York, NY 10019 December 18, 2014 Echo Therapeutics, Inc. 8 Penn Center 1628 JFK Boulevard Suite 300 Philadelphia, PA 19103 Re: Investment in Echo Therapeutics, Inc. Gentlemen: This Letter of Agreement, including the Exhibits attached hereto (collectively, this “Agreement”), sets for
March 31, 2015	NT 10-K	Echo Therapeutics THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. Echo Therapeutics, Inc. - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 00023017 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ x ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N
February 18, 2015	EX-3.1	CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS SERIES F CONVERTIBLE PREFERRED STOCK ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) EXHIBIT 3.1 CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES F CONVERTIBLE PREFERRED STOCK OF ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Echo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), hereby certifies that the Board of Directors of the Company (the “Board”), pursuant t
February 18, 2015	EX-10.1	REIMBURSEMENT AGREEMENT EXHIBIT 10.1 REIMBURSEMENT AGREEMENT REIMBURSEMENT AGREEMENT, dated as of February 12, 2015, by and between Echo Therapeutics, Inc., a Delaware corporation (the “Company”) and Platinum Management (NY) LLC, a New York limited liability company (“Platinum”). RECITALS: WHEREAS, during 2014, Platinum provided $500,000 on a non-recourse basis (the “Loan”) to two of the Company’s directors which was use
February 18, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
February 18, 2015	EX-4.1	FORM OF WARRANT AGREEMENT EXHIBIT 4.1 FORM OF WARRANT AGREEMENT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUA
February 5, 2015	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission F
February 4, 2015	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2015 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission F
January 6, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
January 6, 2015	EX-99.1	Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy Exhibit 99.1 Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy Philadelphia, PA, January 6, 2015 – Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive glucose monitoring and associated technologies, announced today that the Company rehired key members of its Research & Development team to support the implementation of
December 30, 2014	EX-10.1	EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into effective as of December 22, 2014 (the “Effective Date”), by and between Echo Therapeutics, Inc., a Delaware corporation with a place of business at 8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 (the “Company” or “Echo”) and Scott W. Hollander, residing at 5 Caroline Drive
December 30, 2014	EX-99.1	Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer Exhibit 99.1 Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer Philadelphia, PA, December 23, 2014 – Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring and associated technologies, today announced that Scott W. Hollander has been appointed Chief Executive Officer effective December 22, 2014.
December 30, 2014	EX-99.2	Echo Therapeutics Appoints Alan W. Schoenbart as Chief Financial Officer Exhibit 99.2 Echo Therapeutics Appoints Alan W. Schoenbart as Chief Financial Officer Philadelphia, PA, December 30, 2014 – Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring and associated technologies, today announced that Alan W. Schoenbart, CPA, a senior executive with more than thirty years of financial management experie
December 30, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
December 30, 2014	EX-10.2	EMPLOYMENT AGREEMENT Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into effective as of December 29, 2014 (the “Effective Date”), by and between Echo Therapeutics, Inc., a Delaware corporation with a place of business at 8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 (the “Company” or “Echo”) and Alan W. Schoenbart, residing at 1203 River Road
December 23, 2014	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - DECEMBER 22, 2014 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 8)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan
December 23, 2014	EX-99.1	Platinum Partners Value Arbitrage Fund L.P. c/o Platinum Partners 250 West 55th Street, 14th Floor New York, NY 10019 Exhibit 99.1 EXECUTION VERSION Platinum Partners Value Arbitrage Fund L.P. c/o Platinum Partners 250 West 55th Street, 14th Floor New York, NY 10019 December 18, 2014 Echo Therapeutics, Inc. 8 Penn Center 1628 JFK Boulevard Suite 300 Philadelphia, PA 19103 Re: Investment in Echo Therapeutics, Inc. Gentlemen: This Letter of Agreement, including the Exhibits attached hereto (collectively, this “Agre
December 23, 2014	EX-99.3	CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS SERIES F CONVERTIBLE PREFERRED STOCK ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Exhibit 99.3 CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES F CONVERTIBLE PREFERRED STOCK OF ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Echo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), hereby certifies that the Board of Directors of the Company (the “Board”), pursuant
December 23, 2014	EX-99.2	SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTORS LISTED ON THE SIGNATURE PAGES HERETO ECHO THERAPEUTICS, INC. DECEMBER 18, 2014 TABLE OF CONTENTS Exhibit 99.2 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTORS LISTED ON THE SIGNATURE PAGES HERETO AND ECHO THERAPEUTICS, INC. DECEMBER 18, 2014 TABLE OF CONTENTS Page SECTION 1. INTERPRETATION OF THIS AGREEMENT 1 1.1 Defined Terms 1 SECTION 2. AUTHORIZATION OF SHARES; PURCHASE AND SALE OF SHARES 4 2.1 Authorization of Securities 4 2.2 Issuance of Securities 4 2.3 Closing and Closing Dat
December 23, 2014	EX-99.4	FORM OF WARRANT AGREEMENT Exhibit 99.4 FORM OF WARRANT AGREEMENT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
December 19, 2014	EX-99.1	By Electronic Delivery to: [email protected] Exhibit 99.1 By Electronic Delivery to: [email protected] December 18, 2014 Ms. Christine Olimpio Director, Investor Relations and Corporate Communications Echo Therapeutics, Inc. 8 Penn Center 1628 JFK Blvd., Suite 300 Philadelphia, PA 19103 Re: Echo Therapeutics, Inc. (the "Company") Nasdaq Symbol: ECTE Dear Ms. Olimpio: On November 6, 2014, Staff notified the Company that its common stock fai
December 19, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
December 12, 2014	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission F
December 12, 2014	EX-16.1	December 9, 2014 Exhibit 16.1 December 9, 2014 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read the statements made by Echo Therapeutics, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Echo Therapeutics, Inc. dated December 8, 2014. We agree with the statements
November 26, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
November 20, 2014	10-Q/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q /A Amendment No.
November 19, 2014	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .
November 14, 2014	NT 10-Q	ECTE / Echo Therapeutics, Inc. NT 10-Q - - THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
November 7, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission F
November 3, 2014	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission F
October 20, 2014	CORRESP	ECTE / Echo Therapeutics, Inc. CORRESP - - Kleinberg, Kaplan, Wolff & Cohen, P.C. 551 Fifth Avenue New York, NY 10176 P: 212.986.6000 www.kkwc.com Writer’s E-Mail: [email protected] Writer’s Direct Dial: 212.880.9865 October 20, 2014 VIA EMAIL AND EDGAR Daniel F. Duchovny Office of Mergers and Acquisitions Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Echo Therapeutics, Inc. Revised Preliminary Proxy S
October 20, 2014	PRRN14A	ECTE / Echo Therapeutics, Inc. PRRN14A - - PRELIMINARY COPY SUBJECT TO COMPLETION DATED OCTOBER 20 , 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
October 16, 2014	PRER14A	ECTE / Echo Therapeutics, Inc. PRER14A - - PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Revised Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-
October 15, 2014	CORRESP	ECTE / Echo Therapeutics, Inc. CORRESP - - Keith E. Gottfried Partner 202.739.5947 [email protected] October 14, 2014 VIA E-MAIL AND EDGAR AS CORRESP Mr. Daniel F. Duchovny Special Counsel Office of Mergers and Acquisitions United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Echo Therapeutics, Inc. Soliciting Materials filed pursuant to Rule 14a-12 Filed October 2 and 6, 2014 File No. 001
October 14, 2014	PRRN14A	ECTE / Echo Therapeutics, Inc. PRRN14A - - PRELIMINARY COPY SUBJECT TO COMPLETION DATED OCTOBER 13 , 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
October 6, 2014	DEFA14A	ECTE / Echo Therapeutics, Inc. DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
October 6, 2014	DFAN14A	ECTE / Echo Therapeutics, Inc. DFAN14A - - OCTOBER 6, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
October 2, 2014	DEFA14A	ECTE / Echo Therapeutics, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
September 29, 2014	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - SEPTEMBER 29, 2014 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 7)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan
September 29, 2014	PREC14A	ECTE / Echo Therapeutics, Inc. PREC14A - - SEPTEMBER 29, 2014 PRELIMINARY COPY SUBJECT TO COMPLETION DATED SEPTEMBER 29, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
September 29, 2014	DFAN14A	ECTE / Echo Therapeutics, Inc. DFAN14A - - SEPTEMBER 29, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
September 24, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
September 24, 2014	EX-99.1	Echo Therapeutics Suspends Operations To Conserve Liquidity Exhibit 99.1 Echo Therapeutics Suspends Operations To Conserve Liquidity Philadelphia, PA, September 23, 2014 – Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced that, as it believes that its current liquidity is insufficient to fund its needs beyond September 30, 2014, it has suspended its product development, research, manufacturing and clinical programs and opera
September 18, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
September 17, 2014	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - SEPTEMBER 17, 2014 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan
August 19, 2014	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fi
August 19, 2014	EX-99.1	Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update 40%-50% Monthly Cash Burn Reduction Initiatives Implemented Increased Focus on Key Symphony CGM System Enhancements Exhibit 99.1 Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update 40%-50% Monthly Cash Burn Reduction Initiatives Implemented Increased Focus on Key Symphony CGM System Enhancements Philadelphia, PA – August 14, 2014 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless cont
August 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014.
August 14, 2014	EX-10.1	THIRD AMENDMENT TO CONSULTING AGREEMENT Exhibit 10.1 THIRD AMENDMENT TO CONSULTING AGREEMENT This THIRD AMENDMENT TO CONSULTING AGREEMENT is entered into as of April 3, 2014 (the “Amendment”) by and between Echo Therapeutics, Inc., a Delaware corporation (the “Company”), and Robert F. Doman, an individual (“Consultant”). RECITALS WHEREAS, reference is hereby made to the Consulting Agreement entered into as of August 26, 2013, as amended
August 11, 2014	PRE 14A	ECTE / Echo Therapeutics, Inc. PRE 14A - - PRELIMINARY 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
July 29, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission File
July 29, 2014	EX-3.2	AMENDED AND RESTATED BY-LAWS ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through July 24, 2014 TABLE OF CONTENTS Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through July 24, 2014 TABLE OF CONTENTS Page Article 1 Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 List of Stockholders 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 Article 2 Dire
July 16, 2014	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2014 Echo Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission File
July 16, 2014	EX-10.1	July 15, 2014 Exhibit 10.1 July 15, 2014 Charles Bernhardt 23 Birch Road Malvern, PA 19355 RE: Interim Chief Financial Officer position Dear Charles: We are pleased to offer you the temporary position of Interim Chief Financial Officer at Echo Therapeutics, Inc. (the “Company”), reporting to the Company’s Chief Executive Officer. Your base salary will be $220,000 per year. This is a full time temporary position
July 15, 2014	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - JULY 15, 2014 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan
July 2, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission File
June 27, 2014	EX-3.2	AMENDED AND RESTATED BY-LAWS ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through June 24, 2014 TABLE OF CONTENTS Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through June 24, 2014 TABLE OF CONTENTS Page Article 1 Stockholders 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 List of Stockholders 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 Article 2 Direct
June 27, 2014	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fi
June 27, 2014	EX-10.1	DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT Exhibit 10.1 DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This AGREEMENT (this “Agreement”) is made effective as of June 24, 2014, by and between Echo Therapeutics, Inc., a Delaware corporation (the “Corporation”), and , a natural person (“Indemnitee”). Each of the Corporation and the Indemnitee is sometimes referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, Indemnitee i
June 25, 2014	EX-10.1	DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT Exhibit 10.1 DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This AGREEMENT (this “Agreement”) is made effective as of June 24, 2014, by and between Echo Therapeutics, Inc., a Delaware corporation (the “Corporation”), and , a natural person (“Indemnitee”). Each of the Corporation and the Indemnitee is sometimes referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, Indemnitee i
June 25, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission File
June 25, 2014	EX-3.2	AMENDED AND RESTATED BY-LAWS ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through June 24, 2014 TABLE OF CONTENTS Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ECHO THERAPEUTICS, INC. A Delaware Corporation As amended and restated through June 24, 2014 TABLE OF CONTENTS Page Article 1 Stockholders 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 List of Stockholders 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 Article 2 Direct
June 20, 2014	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - JUNE 20, 2014 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan
June 11, 2014	CORRESP	- Alston&Bird llp The Atlantic Building 950 F Street, NW Washington, DC 20004-1404 202-756-3300 Fax:202-756-3333 www.
June 11, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 11, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 10, 2014	DFAN14A	- JUNE 10, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
June 9, 2014	DEFA14A	- DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 9, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 6, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 5, 2014	CORRESP	- Alston&Bird llp The Atlantic Building 950 F Street, NW Washington, DC 20004-1404 202-756-3300 Fax:202-756-3333 www.
June 5, 2014	DEFA14A	- DEFA14A 1 ectedefa14ajune52014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ ] Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (
June 4, 2014	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 4, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 30, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 30, 2014	DEFA14A	- DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 30, 2014	DFAN14A	DFAN14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 30, 2014	DFAN14A	SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 30, 2014	DFAN14A	- MAY 30, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 29, 2014	DFAN14A	- MAY 29, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 27, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 27, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 22, 2014	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 22, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 19, 2014	DFAN14A	- MAY 19, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 16, 2014	DEFC14A	- MAY 16, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 16, 2014	DEFA14A	- DEFA14A 1 ectedefa14a2may162014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only
May 16, 2014	DEFA14A	- DEFA14A 1 ectedefa14amay162014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permi
May 13, 2014	EX-99.1	Echo Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Regulatory and Product Development Update Company to Host Conference Call Today, May 9, 2014 at 9:00 AM EDT Exhibit 99.1 Echo Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Regulatory and Product Development Update Company to Host Conference Call Today, May 9, 2014 at 9:00 AM EDT Philadelphia, PA – May 9, 2014 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, toda
May 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission File N
May 12, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 12, 2014	DEFA14A	- DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 12, 2014	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014.
May 9, 2014	CORRESP	- Alston&Bird llp The Atlantic Building 950 F Street, NW Washington, DC 20004-1404 202-756-3300 Fax:202-756-3333 www.
May 9, 2014	DEFC14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 6, 2014	PRER14A	- REVISED PRELIMINARY PROXY STATEMENT, SUBJECT TO COMPLETION DATED MAY 6, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 6, 2014	CORRESP	- The Atlantic Building 950 F Street, NW Washington, DC 20004-1404 202-756-3300 Fax:202-756-3333 www.
May 1, 2014	EX-10.31	LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT ECHO THERAPEUTICS, INC. MEDICAL TECHNOLOGIES INNOVATION ASIA, LTD. Exhibit 10.31 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between ECHO THERAPEUTICS, INC. and MEDICAL TECHNOLOGIES INNOVATION ASIA, LTD. -1- TABLE OF CONTENTS 1. Definitions Page 1.1 Defined Terms 2. Development Project 2.1 Commencement of the Project 2.2 Amendments to the Work Plan 2.3 Transfer of Echo Materials and Echo Know-How 2.4 Performance by MTIA 2.5 Disclosure of Results 2.6 Repo
May 1, 2014	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A Amendment No.
April 29, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2014	PRRN14A	- APRIL 28, 2014 PRRN14A 1 echoprrn14a-042514.htm APRIL 28, 2014 PRELIMINARY COPY SUBJECT TO COMPLETION DATED APRIL 28 , 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant [ ] Filed by a Party Other than the Registrant [x] Check the Appropriate Bo
April 28, 2014	CORRESP	- Writer’s E-Mail: [email protected] Writer’s Direct Dial: 212.880.9865 April 28, 2014 VIA EMAIL AND EDGAR Geoff Kruczek Office of Mergers and Acquisitions Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Echo Therapeutics, Inc. Preliminary Proxy Statement filed by Platinum Partners Value Arbitrage Fund, L.P., Platinum Long Term Growth VII, LLC, Platinum Partners L
April 24, 2014	PREC14A	- PREC14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 24, 2014	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 23, 2014	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 21, 2014	DFAN14A	- APRIL 21, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
April 17, 2014	CORRESP	- Kleinberg, Kaplan, Wolff & Cohen, P.C. 551 Fifth Avenue New York, NY 10176 April 17, 2014 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Office of Mergers and Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Re: Platinum Partners Value Arbitrage Fund, LP (the “Fund”) Preliminary Proxy Statement on Schedule 14A Dear Sir or Madam: Transmitted herewith on behalf of the
April 17, 2014	PREC14A	- APRIL 17, 2014 PRELIMINARY COPY SUBJECT TO COMPLETION DATED APRIL 17, 2014 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
April 15, 2014	DEF 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 8, 2014	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - APRIL 8, 2014 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.3)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg,
April 7, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission File
April 1, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fil
April 1, 2014	EX-99.1	Echo Therapeutics, Inc. Announces 2013 Financial Results Company to Host Conference Call Today, March 27, 2014 at 9:00 AM ET Exhibit 99.1 Echo Therapeutics, Inc. Announces 2013 Financial Results Company to Host Conference Call Today, March 27, 2014 at 9:00 AM ET Philadelphia, PA – March 27, 2014 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended Decemb
March 28, 2014	EX-10.31	LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT ECHO THERAPEUTICS, INC. MEDICAL TECHNOLOGIES INNOVATION ASIA, LTD. Exhibit 10.31 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between ECHO THERAPEUTICS, INC. and MEDICAL TECHNOLOGIES INNOVATION ASIA, LTD. -1- TABLE OF CONTENTS 1. Definitions. 1.1 Defined Terms 2. Development Project. 2.1 Commencement of the Project 2.2 Amendments to the Work Plan 2.3 Transfer of Echo Materials and Echo Know-How 2.4 Performance by MTIA 2.5 Disclosure of Results 2.6 Reports
March 28, 2014	EX-10.32	SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR LISTED ON THE SIGNATURE PAGE HERETO ECHO THERAPEUTICS, INC. DECEMBER 10, 2013 Exhibit 10.32 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR LISTED ON THE SIGNATURE PAGE HERETO AND ECHO THERAPEUTICS, INC. DECEMBER 10, 2013 -1- TABLE OF CONTENTS SECTION 1. INTERPRETATION OF THIS AGREEMENT 1.1. Defined Terms SECTION 2. AUTHORIZATION OF SHARES; PURCHASE AND SALE OF SHARES 2.1. Authorization of Securities 2.2. Issuance of Securities 2.3. Closing and Closing Date 2.4. D
March 28, 2014	EX-10.34	SECOND AMENDMENT TO CONSULTING AGREEMENT Exhibit 10.34 SECOND AMENDMENT TO CONSULTING AGREEMENT This SECOND AMENDMENT TO CONSULTING AGREEMENT is entered into as of December 26, 2013 (the “Amendment”) by and between Echo Therapeutics, Inc., a Delaware corporation (the “Company”), and Robert F. Doman, an individual (“Consultant”). RECITALS WHEREAS, reference is hereby made to the Consulting Agreement entered into as of August 26, 2013 (as
March 28, 2014	EX-4.8	ECHO THERAPEUTICS, INC. COMMON STOCK PURCHASE, WARRANT Exhibit 4.8 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 28, 2014	EX-10.35	AMENDMENT TO SECURITIES PURCHASE AGREEMENT LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 10.35 AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT THIS AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is dated as of January 30, 2014, by and between Echo Therapeutics, Inc., having offices at 8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 US
March 28, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) R ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2013 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 000-23017 ECHO THERAPEUTICS, INC.
March 28, 2014	EX-10.33	SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR LISTED ON THE SIGNATURE PAGE HERETO ECHO THERAPEUTICS, INC. DECEMBER 10, 2013 Exhibit 10.33 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR LISTED ON THE SIGNATURE PAGE HERETO AND ECHO THERAPEUTICS, INC. DECEMBER 10, 2013 -1- TABLE OF CONTENTS Page SECTION 1. INTERPRETATION OF THIS AGREEMENT 1.1. Defined Terms SECTION 2. AUTHORIZATION OF SHARES; PURCHASE AND SALE OF SHARES 2.1. Authorization of Securities 2.2. Issuance of Securities 2.3. Closing and Closing Date 2
March 28, 2014	EX-3.6	CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS SERIES E CONVERTIBLE PREFERRED STOCK ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Exhibit 3.6 CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES E CONVERTIBLE PREFERRED STOCK OF ECHO THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Echo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), hereby certifies that the Board of Directors of the Company (the “Board”), pursuant t
March 28, 2014	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Sontra Medical, Inc. Delaware
March 6, 2014	EX-99	Echo Therapeutics Adds New Member to Board of Directors EX-99 2 ex99-03062014040306.htm Exhibit 99.1 Echo Therapeutics Adds New Member to Board of Directors Philadelphia, PA – February 28, 2014 – Echo Therapeutics, Inc. (Nasdaq: ECTE) (“Echo”), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo’s Board o
March 6, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
February 4, 2014	8-K	Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2014 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission F
January 2, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 26, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
December 26, 2013	8-K	Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 23, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
December 19, 2013	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - AMENDMENT NO. 2 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg
December 17, 2013	RW	- ECHO THERAPEUTICS, INC. 8 Penn Center 1628 JFK Blvd., Suite 300 Philadelphia, PA 19103 December 17, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.E. Washington, D.C. 20549 Re: Echo Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-192630) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 193
December 13, 2013	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
December 13, 2013	EX-99.1	Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA) Echo to receive a $10 million cash investment from MTIA and Platinum Partners Company will withdraw the offering identified in recent Form S-1 filing Exhibit 99.1 Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA) Echo to receive a $10 million cash investment from MTIA and Platinum Partners Company will withdraw the offering identified in recent Form S-1 filing Philadelphia, PA – December 10, 2013 – Echo Therapeutics, Inc. (Nasdaq: ECTE) (“Echo”), a medical device company developing its Symphony®
December 2, 2013	EX-21.1	SUBSIDIARIES OF THE COMPANY Exhibit 21.1 SUBSIDIARIES OF THE COMPANY Name Jurisdiction of Incorporation Sontra Medical, Inc. Delaware
December 2, 2013	S-1	Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on December 2, 2013 Registration No.
December 2, 2013	EX-4.1	-1- Exhibit 4.1 -1-
November 7, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013.
November 7, 2013	EX-10.1	FIRST AMENDMENT TO CONSULTING AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO CONSULTING AGREEMENT This FIRST AMENDMENT TO CONSULTING AGREEMENT is entered into as of October 3, 2013 (the “Amendment”) by and between Echo Therapeutics, Inc., a Delaware corporation (the “Company”), and Robert F. Doman, an individual (“Consultant”). RECITALS WHEREAS, reference is hereby made to the Consulting Agreement entered into as of August 26, 2013 (as amend
October 15, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fi
October 11, 2013	CORRESP	- Echo Therapeutics, Inc. 1628 JFK Blvd., Suite 300 Philadelphia, PA 19103 October 11, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance One Station Place 100 F Street, NE Washington, DC 20549-6010 Attn: Mr. Brian Cascio Re: Echo Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 18, 2013 File No. 001-35218 Ladies and Ge
October 3, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events - ECTE 8K OCT 3 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission
October 3, 2013	EX-99.1	Echo Therapeutics Provides Corporate Update and Implements Substantial Cost Reduction Initiatives Exhibit 99.1 Echo Therapeutics Provides Corporate Update and Implements Substantial Cost Reduction Initiatives Philadelphia, PA – October 3, 2013 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, today announced a corporate update covering Company activities, expected near-term a
September 3, 2013	SC 13D/A	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - AUGUST 30, 2013 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.1)* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Christopher P. Davis Kleinberg,
August 29, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fi
August 29, 2013	EX-10.1	CONSULTING AGREEMENT Exhibit 10.1 Execution Version CONSULTING AGREEMENT THIS CONSULTING SERVICES AGREEMENT, is entered into as of August 26, 2013 by and between Echo Therapeutics, Inc., a Delaware corporation ("the "Company"), and Robert F. Doman, an individual ("Consultant"). BACKGROUND The Company wishes to obtain the services of Consultant for certain purposes, and Consultant wishes to provide such services, all s
August 29, 2013	EX-99.1	Echo Therapeutics Announces Management Changes Robert Doman to Assume Role of Executive Chairman and Interim Chief Executive Officer Exhibit 99.1 Echo Therapeutics Announces Management Changes Robert Doman to Assume Role of Executive Chairman and Interim Chief Executive Officer Philadelphia, PA – August 26, 2013 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its non-invasive Symphony® CGM System as a needle-free, wireless continuous glucose monitoring system, today announced that its Chief Executive Officer, Pre
August 9, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2013 Echo Therapeutics, Inc. (Exact name of Company as specified in its charter) Delaware 000-23017 41-1649949 (State or other jurisdiction of Incorporation) (Commission Fil
August 9, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .
August 9, 2013	EX-99.1	Echo Therapeutics Announces Second Quarter 2013 Financial Results Exhibit 99.1 Echo Therapeutics Announces Second Quarter 2013 Financial Results Philadelphia, PA – August 8, 2013 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, today announced financial results for the quarter ended June 30, 2013. Echo’s Quarterly Report on Form 10
July 15, 2013	SC 13D	ECTE / Echo Therapeutics, Inc. / Platinum Partners Value Arbitrage Fund, LP - JULY 12, 2013 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Echo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 27876L107 (CUSIP Number) Eric S. Wagner, Esq. Kleinberg,

ECTE / Echo Therapeutics Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)